Instem shares soar following US government contract win

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further nine years, giving a possible total contract value for all 10 years of between $6.2m and $7.6m.

The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in a further material increase in revenue, Instem reported.

The NTP is an inter-agency programme designed to coordinate toxicology research and development across the United states Department of Health and Human Services.

The NTP is managed by the NIEHS and supported by the US Food and Drug Administration and the Centers for Disease Control and Prevention.

Phil Reason, Chief Executive Officer of Instem, said: "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices.

"Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations. The accessibility of Provantis data will also enable the NIEHS to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

Instem is a supplier of IT applications to the early development healthcare market.

Its share price was up 33.33% to 130p at 12:05 on Thursday.

MF

Recommended

How to profit from pampered pets beyond the pandemic
Share tips

How to profit from pampered pets beyond the pandemic

Covid-19 has greatly boosted ownership. But the market had been expanding for years, and demographic, cultural and medical trends all point to long-te…
30 Jul 2021
Share tips of the week – 30 July
Share tips

Share tips of the week – 30 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Jul 2021
Robinhood is going public – should you invest?
US stockmarkets

Robinhood is going public – should you invest?

Online stockbroking app Robinhood is going public on the US stock exchange. Saloni Sardana looks at whether it's worth a punt.
29 Jul 2021
Three sustainable stocks that are doing well by doing good
Share tips

Three sustainable stocks that are doing well by doing good

Professional investor Peter Michaelis of the Liontrust Sustainable Investment Team picks three stocks to buy that are helping to create a cleaner, saf…
26 Jul 2021

Most Popular

Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021